engineered T cells with a synNotch receptor for HER2 that controlled the expression of a CAR for the same antigen, which functioned well both in vitro and in vivo with sharp discrimination between cancer cells and normal cells on the basis of HER2 expression. The gene discussed is ERBB2; the disease is cancer.